pharming


Also found in: Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.

pharm·ing 1

 (fär′mĭng)
n.
The production of pharmaceuticals from genetically altered plants or animals.

[Blend of pharmaceutical and farming, gerund of farm.]

pharm v.

pharm·ing 2

 (fär′mĭng)
n.
A method of identity theft in which one sets up a website closely resembling a legitimate website, as of a bank, and surreptitiously redirects users trying to visit the authentic website to the fake one to trick them into revealing passwords or other personal information.

[Alteration (influenced by phish) of farm (after the server farms generally used to launch pharming attacks).]

pharm v.

pharming

(ˈfɑːmɪŋ)
n
(Agriculture) the practice of rearing or growing genetically-modified animals or plants in order to develop pharmaceutical products
[C20: blend of pharmaceutical + farming]

pharming

(ˈfɑːmɪŋ)
n
(Telecommunications) the practice of redirecting computer users from legitimate websites to fraudulent ones for the purposes of extracting confidential data
[C21: from farming in the sense of cultivating and harvesting; computer-hacker slang often replaces f with ph]

pharming

A method of committing fraud by redirecting the customers of a legitimate online business, such as a bank, to a website where details such as account numbers and passwords may be recorded. The website to which customers are redirected is often designed to resemble the legitimate company’s website. Unlike phishing, pharming is aimed at every person who accesses the target website.
References in periodicals archive ?
Pharming Group (PHARM:EN Amsterdam), a Netherlands-based biotechnology company, has extended a distribution agreement with Cytobioteck.
Biotech company Pharming Group NV ( Pharming ) announced today that it has received approval from the European Medicines Agency (EMA) for Sanofi Chimie to manufacture drug substance for Pharming s product Ruconest at their Aramon (France) site.
SeeNews) - Nov 7, 2012 - Dutch biotechnology firm Pharming Group NV (AMS:PHARM) and US Santarus Inc (NASDAQ:SNTS) unveiled today promising top-line Phase III data for Ruconest (recombinant human C1 esterase inhibitor) in acute hereditary angioedema.
Dutch biotech firm Pharming (AMS:PHARM) said yesterday it has completed the sale of a 49% stake in biopharmaceutical company DNage BV to the company's original owners.
The NameLock, NameWatch and NameSecure solutions are intended to prevent and identify pharming attacks, providing a solution against thefts, hijacking and takeover of domain names and websites.
has added pharming protection to its online identity protection products.
Pharming has obtained patents and licenses on various products and technologies, including the production and purification of recombinant human fibrinogen and recombinant tissue sealant compositions.
Biotech company Pharming Group NV (NYSE:PHARM) (Euronext: PHARM) reported today a net loss of EUR5.
Biotech company Pharming Group NV (Euronext: PHARM) today announced the receipt of a USD10m milestone payment.
Biotech company Pharming Group NV ( Pharming or the Company ) today announced that following the announcement by Pharming and Santarus on November 7, 2012 that the pivotal Phase III clinical study of RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE) met its primary endpoint, and in accordance with the terms of the license agreement between Pharming and Santarus, a US$10 million milestone has now been paid to Pharming.
As a result of the agreement between the two companies, Rein Strijker, senior vice president corporate development and strategy with Pharming will become a member of the Board of Supervisory Directors of AM-Pharma.